• 2025
  • 2024
  • 2023
  • 2022
  • 2021

back

January 14, 2025

Notification of co-promotion agreement termination of Minirin Melt and Desmopressin formulations

Ferring Pharmaceuticals Co., Ltd.
Kissei Pharmaceutical Co., Ltd.



Ferring Pharma Co., Ltd. (Head office: Minato, Tokyo; President and CEO: John Pulvar; "Ferring") and Kissei Pharmaceutical Co., Ltd. (Head office: Matsumoto, Nagano; Chairman and CEO: Mutsuo Kanzawa; "Kissei") announce that they will terminate their co-promotion agreement for "Minirin Melt®" and "Desmopressin formulations" (see table below). The active ingredient of the aforesaid drugs is desmopressin acetate hydrate, which was developed by Ferring.

Ferring and Kissei have had a co-promotion in Japan since September 2019, and with the termination of this co-promotion agreement, Kissei will suspend promotion activities for the drug on March 31, 2025. Furthermore, Ferring will be solely responsible for promotion activities for these drugs from April 1, 2025.

Brand Name

Indication

MINIRIN MELT® OD Tablets 25μg and 50μg

Nocturia due to nocturnal polyuria in males

MINIRIN MELT® OD Tablets 60μg, 120μg, and 240μg

Nocturnal enuresis resulted from decrease of urine osmolality or urine specific gravity*, central diabetes insipidus

* 120μg and 240μg only

DESMOPRESSIN Spray 2.5 Ferring

Central diabetes insipidus

DESMOPRESSIN injection 4 Ferring

Hemostatic management of spontaneous or traumatic hemorrhage and bleeding during tooth extraction or operation in the patients with following diseases:
 Mild/moderate hemophilia A (with 2% or higher factor VIII coagulative activity)
 Type I/Type IIA von Willebrand disease

"DESMOPRESSIN Intranasal 0.01% Kyowa" and "DESMOPRESSIN injection 4 Kyowa" have already been discontinued from production and sales.



《Reference》

About Ferring Pharmaceuticals Co.,Ltd

Ferring Pharmaceuticals is a privately owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine and maternal health, and in areas of gastroenterology and urology. We are at the forefront of innovation in microbiome-based therapeutics and uro-oncology intravesical gene therapy. Ferring was founded in 1950 and employs more than 7,000 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which markets its medicines in over 100 countries.

For more details of Ferring Pharmaceuticals, please visit https://www.ferring.co.jp/.

About Kissei Pharmaceutical Co., Ltd

Kissei is a Japanese pharmaceutical company based on the management philosophy "contributing to society through high-quality, innovative pharmaceutical products" and "serving society through our employees." As a strong R&D-oriented corporation, it concentrates on providing innovative pharmaceuticals to patients worldwide in the focus fields of urology, nephrology/dialysis, gynecology and rare/intractable diseases.

For more details about Kissei Pharmaceutical Co., Ltd., please visit https://www.kissei.co.jp/.